To include your compound in the COVID-19 Resource Center, submit it here.

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

Salix’s Mark McKenna will become CEO of gastroenterology and autoimmune disease company Prometheus Biosciences Inc. (San Diego, Calif.), formerly known as Precision IBD Inc. McKenna was president at Salix Pharmaceuticals Ltd., a subsidiary of Bausch Health Companies Inc.

Read the full 382 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers